Gilde Healthcare recently announced a new investment fund with €600 million in commitments: Gilde Healthcare Venture&Growth VI. This new fund focuses on fast-growing companies developing solutions for better care at a lower cost. Plus, Gilde Healthcare invests in companies in Europe and North America active in digital healthcare, medical technology (MedTech) and therapeutics.
This fund is backed by a balanced mix of international investors, including corporates, banks, pension funds, insurers, fund-of-funds, sovereign wealth funds, endowments, family offices, entrepreneurs and the Gilde team.
The healthcare expenditure in the Western World continues to grow – which already exceeds 20% of GDP in the United States. And Gilde Healthcare’s mission to invest in better care at lower cost, is supported by the recently established Impact Council, chaired by the former executive director of the European Medicines Agency (EMA).
The new fund is going to invest €10 million to €60 million per new portfolio company. And together with the last Venture&Growth fund (closed in 2020) and Gilde Healthcare Private Equity IV (closed in 2022), Gilde Healthcare has raised €1.5 billion in capital over the last three years.
KEY QUOTES:
“We are pleased with the strong interest from investors who support our mission. Innovations that improve the quality of care but also keep it affordable are essential to ensure access to healthcare. Our broad strategy, covering digital health, MedTech and therapeutics, results in a holistic approach allowing us to select the most optimal and cost effective solution for the individual patient. With a team of sector experts, we help companies to further scale medical innovations and to make them accessible globally.”
- Pieter van der Meer, Managing Partner at Gilde Healthcare
